By comparison retatrutide reached 24 percent weight loss at 48 weeks, twelve weeks earlier than the mazdutide data cutoff. That 24 percent figure already excludes the placebo response. The nearest matching number for mazdutide is 17 percent, so the result still looks strong.
A press release describes a study in which mazdutide at 9 mg produced up to 20.1 percent weight loss among Chinese adults with obesity and met its main and all secondary goals. The sponsor intends to request approval for a weekly maximum of 9 mg rather than the current 6 mg limit. In people without diabetes who started with at least 10 percent liver fat, the 9 mg arm showed a 71.9 percent average drop in liver fat by week 60 while placebo rose 5.1 percent. I recall tirzepatide achieving only an 8 percent reduction, which suggests GIPR activity is required for large liver-fat decreases. The same 9 mg group lost 20.08 percent of body weight at week 60 compared with 2.81 percent on placebo. Weight kept falling steadily through the treatment period without leveling off.